Cann Group Ltd Asset Resilience Ratio
Cann Group Ltd asset resilience ratio. Cann Group Ltd (CAN) has an Asset Resilience Ratio of 1.72% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Cann Group Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Cann Group Ltd (2016–2025)
Asset resilience ratio of Cann Group Ltd from 2016 to 2025. This chart shows how Cann Group Ltd's Asset Resilience Ratio has changed over time. Read CAN current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Cann Group Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see CAN total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$955.00K | 1.72% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$955.00K | 1.72% |
Asset Resilience Insights
- Limited Liquidity: Cann Group Ltd maintains only 1.72% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Cann Group Ltd Industry Peers by Asset Resilience Ratio
Compare Cann Group Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Cann Group Ltd Asset Resilience Ratio by Year (2016–2025)
Cann Group Ltd asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Cann Group Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 0.01% | AU$10.00K ≈ $7.08K |
AU$78.79 Million ≈ $55.75 Million |
-1.76pp |
| 2024-06-30 | 1.77% | AU$1.64 Million ≈ $1.16 Million |
AU$92.77 Million ≈ $65.64 Million |
+1.18pp |
| 2023-06-30 | 0.59% | AU$765.00K ≈ $541.29K |
AU$129.47 Million ≈ $91.61 Million |
-0.78pp |
| 2022-06-30 | 1.37% | AU$1.91 Million ≈ $1.35 Million |
AU$139.66 Million ≈ $98.82 Million |
-1.60pp |
| 2021-06-30 | 2.97% | AU$3.02 Million ≈ $2.14 Million |
AU$101.79 Million ≈ $72.02 Million |
+1.04pp |
| 2020-06-30 | 1.92% | AU$1.47 Million ≈ $1.04 Million |
AU$76.40 Million ≈ $54.06 Million |
-54.57pp |
| 2019-06-30 | 56.49% | AU$46.39 Million ≈ $32.82 Million |
AU$82.11 Million ≈ $58.10 Million |
-35.27pp |
| 2018-06-30 | 91.76% | AU$79.65 Million ≈ $56.36 Million |
AU$86.80 Million ≈ $61.42 Million |
+18.03pp |
| 2017-06-30 | 73.73% | AU$11.11 Million ≈ $7.86 Million |
AU$15.07 Million ≈ $10.67 Million |
-- |
| 2016-12-31 | 0.00% | AU$0.00 ≈ $0.00 |
AU$15.89 Million ≈ $11.25 Million |
-- |
About Cann Group Ltd
Cann Group Limited, together with its subsidiaries, engages in the breeding, cultivation, manufacture, and sale of medicinal cannabis in Australia and Europe. Its product portfolio includes the Satipharm delivery system for cannabinoids. The company was founded in 2014 and is based in Mildura, Australia.